William Blair analyst Raju Prasad notes that on Thursday, Rocket Pharmaceuticals announced updates from the company’s end-of-Phase 1 meeting with the FDA regarding RP-A501, its Danon disease program. Discussions with the FDA were largely in agreement and seemingly aligned with the agency’s expectations, the analyst states. Prasad believes the FDA discussion commentary signals positive outlook on upcoming design submission of pivotal trial in Danon disease. He has an Outperform rating on the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RCKT:
- Rocket Pharmaceuticals weakness a buying opportunity, says UBS
- Rocket Pharmaceuticals provides update on registration path for RP-A501
- Rocket Pharmaceuticals presents clinical data from LV-based gene therapy program
- TipRanks ‘Perfect 10’ List: These 3 Top-Rated Stocks Could Shine in 2023
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations